JP2017533886A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533886A5
JP2017533886A5 JP2017514635A JP2017514635A JP2017533886A5 JP 2017533886 A5 JP2017533886 A5 JP 2017533886A5 JP 2017514635 A JP2017514635 A JP 2017514635A JP 2017514635 A JP2017514635 A JP 2017514635A JP 2017533886 A5 JP2017533886 A5 JP 2017533886A5
Authority
JP
Japan
Prior art keywords
alkyl
amino
aryl
cycloalkyl
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017514635A
Other languages
English (en)
Japanese (ja)
Other versions
JP6875273B2 (ja
JP2017533886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2015/050910 external-priority patent/WO2016041082A1/en
Publication of JP2017533886A publication Critical patent/JP2017533886A/ja
Publication of JP2017533886A5 publication Critical patent/JP2017533886A5/ja
Priority to JP2021072535A priority Critical patent/JP7204083B2/ja
Application granted granted Critical
Publication of JP6875273B2 publication Critical patent/JP6875273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017514635A 2014-09-17 2015-09-17 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法 Active JP6875273B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021072535A JP7204083B2 (ja) 2014-09-17 2021-04-22 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051883P 2014-09-17 2014-09-17
US62/051,883 2014-09-17
PCT/CA2015/050910 WO2016041082A1 (en) 2014-09-17 2015-09-17 Cytotoxic and anti-mitotic compounds, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021072535A Division JP7204083B2 (ja) 2014-09-17 2021-04-22 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法

Publications (3)

Publication Number Publication Date
JP2017533886A JP2017533886A (ja) 2017-11-16
JP2017533886A5 true JP2017533886A5 (enExample) 2018-11-01
JP6875273B2 JP6875273B2 (ja) 2021-05-19

Family

ID=55454112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514635A Active JP6875273B2 (ja) 2014-09-17 2015-09-17 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法
JP2021072535A Active JP7204083B2 (ja) 2014-09-17 2021-04-22 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021072535A Active JP7204083B2 (ja) 2014-09-17 2021-04-22 細胞傷害性及び抗有糸分裂性化合物、ならびにその使用方法

Country Status (21)

Country Link
US (5) US10450378B2 (enExample)
EP (2) EP3194421B1 (enExample)
JP (2) JP6875273B2 (enExample)
KR (2) KR102494557B1 (enExample)
CN (2) CN107001415B (enExample)
AU (2) AU2015318556C1 (enExample)
BR (1) BR112017005126B1 (enExample)
CA (1) CA2960899C (enExample)
CY (1) CY1124933T1 (enExample)
DK (1) DK3194421T3 (enExample)
ES (1) ES2905569T3 (enExample)
HR (1) HRP20220123T1 (enExample)
HU (1) HUE057768T2 (enExample)
IL (3) IL287645B2 (enExample)
MX (1) MX386008B (enExample)
PL (1) PL3194421T3 (enExample)
PT (1) PT3194421T (enExample)
RS (1) RS62860B1 (enExample)
RU (1) RU2723651C2 (enExample)
SG (1) SG11201702143PA (enExample)
WO (1) WO2016041082A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
SG11201605260VA (en) 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
FI3765525T3 (fi) 2018-03-13 2023-10-16 Zymeworks Bc Inc Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
EP3994150A4 (en) * 2019-07-03 2023-08-02 Iconic Therapeutics LLC ANTI-TISSUE FACTOR-DRUG ANTIBODY CONJUGATES AND RELATED METHODS
CA3081503A1 (en) 2019-12-06 2021-06-06 Zymeworks Inc. Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
JP2025531401A (ja) 2022-09-22 2025-09-19 レプ バイオファーマ カンパニー,リミティド Gpc3抗体薬物複合体及びその使用

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
ES521370A0 (es) 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5094849A (en) 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
AU679479B2 (en) 1992-12-16 1997-07-03 Basf Aktiengesellschaft Dolostatin analog
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP3469580B2 (ja) 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
JP3871713B2 (ja) 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
CA2225325A1 (en) 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
HK1039492A1 (en) 1999-01-28 2002-04-26 Chugai Seiyaku Kabushiki Kaisha Substitute phenethylamine derivatives
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
TWI245034B (en) 2000-07-24 2005-12-11 Matsushita Electric Industrial Co Ltd Capacitor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
CA2479764C (en) 2002-03-22 2013-07-30 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
AU2003263094A1 (en) 2002-04-23 2003-11-10 National Institutes Of Health Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
AU2003275126A1 (en) 2002-09-20 2004-04-08 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
CN1705639A (zh) 2002-09-20 2005-12-07 惠氏控股公司 用于合成微管蛋白抑制剂的中间体的合成方法
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
AU2003295808A1 (en) 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
US7390910B2 (en) 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1670800A1 (en) 2003-09-15 2006-06-21 The University of British Columbia Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
US7078562B2 (en) 2004-01-19 2006-07-18 Mitsubishi Gas Chemical Company, Inc. Adamantane derivatives and resin compositions using the same as raw material
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
JP5198063B2 (ja) 2004-08-26 2013-05-15 アッパラオ・サティアム 新規バイオ開裂性リンカー
CN101039701A (zh) 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
AU2005316844A1 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
MX2007007574A (es) 2004-12-22 2007-07-24 Astrazeneca Ab Derivados de piridina-carboxamida para uso como agentes anticancerosos.
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス, インコーポレイテッド フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
KR20090122439A (ko) 2007-02-21 2009-11-30 메다렉스, 인코포레이티드 단일 아미노산을 갖는 화학적 링커 및 이의 접합체
BRPI0817881A2 (pt) 2007-10-10 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
US20090155289A1 (en) 2007-11-01 2009-06-18 Steve Roberts Furin-cleavable peptide linkers for drug-ligand conjugates
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP2281006B1 (en) 2008-04-30 2017-08-02 Immunogen, Inc. Cross-linkers and their uses
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010010324A1 (en) 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
AU2009317691A1 (en) 2008-11-21 2010-05-27 Kobenhavns Universitet (University Of Copenhagen) Priming of an immune response
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CN102448469A (zh) 2009-05-28 2012-05-09 摩萨纳医疗有限公司 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
NZ598288A (en) 2009-08-28 2014-02-28 Arena Pharm Inc Cannabinoid receptor modulators
RU2609021C2 (ru) 2009-09-25 2017-01-30 Астеллас Фарма Инк. Замещенные соединения амида
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス,インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー/エス ヘテロ二量体抗体Fc含有タンパク質およびその産生方法
CA2801971C (en) * 2010-06-10 2018-07-24 Hans-Georg Lerchen Novel auristatin derivatives and their use
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
ES2531471T3 (es) 2011-02-25 2015-03-16 Lonza Ltd Enlazador ramificado para conjugados de proteínas-fármacos
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
US9200034B2 (en) 2011-03-16 2015-12-01 Council Of Scientific & Industrial Research Oligopeptides and process for preparation thereof
EP2690955A4 (en) * 2011-03-30 2014-10-15 Univ Arizona AURISTATINE TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOCHINOLINE DERIVATIVES AND PRODRUGS THEREOF
EP3501546A3 (de) 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
CN103717595A (zh) 2011-05-27 2014-04-09 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
CA2837840C (en) 2011-06-10 2020-08-04 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US20130190248A1 (en) 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
TWI589592B (zh) * 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
JP6517018B2 (ja) 2012-02-09 2019-05-22 ヴァー2・ファーマシューティカルズ・アンパルトセルスカブVAR2 Pharmaceuticals ApS コンドロイチン硫酸グリカンのターゲティング
EP3925627A1 (en) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
MX363116B (es) 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
US9599265B2 (en) * 2012-06-15 2017-03-21 Stephen B. Maguire Multiple plate quick disconnect sandwich fitting
EP4406612A3 (en) 2012-06-19 2024-10-16 Ambrx, Inc. Anti-cd70 antibody drug conjugates
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
KR20150119848A (ko) 2012-12-21 2015-10-26 바이오얼라이언스 씨.브이. 친수성 자기-희생 링커 및 그것의 포합체
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2015041635A1 (en) * 2013-09-17 2015-03-26 Halliburton Energy Services, Inc. Constant velocity device for downhole power generation
EP3057610B1 (en) 2013-10-15 2021-09-22 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
JP6636925B2 (ja) 2013-12-17 2020-01-29 ノバルティス アーゲー 細胞障害性ペプチドおよびその抱合体
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
SG11201605260VA (en) * 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. 抗体薬物コンジュゲート
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules

Similar Documents

Publication Publication Date Title
HRP20220123T1 (hr) Citotoksični i antimitotički spojevi, te postupci njihove uporabe
JP2016508130A5 (enExample)
ES2765949T3 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CL2023001331A1 (es) Compuestos de aminoácidos y métodos de uso
RU2016130933A (ru) Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
SG11201807765PA (en) Antibody-containing preparation
MX2020009253A (es) Compuestos de aminoacidos y metodos de uso.
PE20210414A1 (es) Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
CY1119827T1 (el) Ακυλαμινο-υποκατεστημενα συντηγμενα παραγωγα κυκλοπεντανο καρβοξυλικου οξεος και η χρηση αυτων ως φαρμακευτικων ουσιων
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
JP2018507197A5 (enExample)
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
PE20141202A1 (es) Compuesto de ciclopropanoamina
JP2013517277A5 (enExample)
CY1117363T1 (el) Σκευασμα αντισωματος κατα abeta
TR201908590T4 (tr) Nitrokatekol türevlerini içeren farmasötik formülasyonlar ve bunların üretimine yönelik yöntemler.
NZ715646A (en) Antibody drug conjugates
CY1115176T1 (el) Ρυθμιστες υποδοχεων τυπου toll
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
PH12015502180A1 (en) Wt1-antigen peptide conjugate vaccine
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
JP2017506234A5 (enExample)
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες